Tuberculosis (TB) treatment challenges in TB-diabetes comorbid patients: a systematic review and meta-analysis

Mahnoor Khattak,Anees ur Rehman,Tuba Muqaddas,Rabia Hussain,Muhammad Fawad Rasool,Zikria Saleem,Mesfer Safar Almalki,Samar Adel Alturkistani,Shuruq Zuhair Firash,Oseid Mohammed Alzahrani,Ammar Abdulraheem Bahauddin,Safa Almarzooky Abuhussain,Muath Fahmi Najjar,Hossameldeen Mahmoud Ali Elsabaa,Abdul Haseeb
DOI: https://doi.org/10.1080/07853890.2024.2313683
IF: 5.348
2024-02-14
Annals of Medicine
Abstract:Background The Directly Observed Treatment-Short Course (DOTS) Programme was implemented by WHO and includes a combination of four anti-tuberculosis (TB) drugs (isoniazid, pyrazinamide, ethambutol and rifampicin) for a period of six months to eradicate the TB infection completely. Diabetes mellitus (DM) is recognized as one of a strong contributor of TB according to World Health Organization (WHO). The presence of diabetes mellitus type 2 (DM type 2) makes TB treatment complicated. Thus, the objective of the current meta-analysis was to identify and quantify the impact of type 2 DM on treatment outcomes of TB patients treated under the DOTS Programme.
medicine, general & internal
What problem does this paper attempt to address?